OBJECTIVE: To determine whether buccal @entity396 during cesarean delivery in conjunction with active management of the third stage of labor reduces the need for additional uterotonic drugs. METHOD: A double-blind, randomized, placebo-controlled trial was performed in Monterrey, Mexico, between February 2008 and December 2013. Eligible @entity1 had risk factors for uterine atony and were to undergo cesarean delivery under epidural block. Using a computer-generated sequence and blocks of six, @entity1 were randomly assigned to receive 400 g @entity396 or 800 g placebo buccally after cord clamping. Both groups received an intravenous @entity398 infusion. The primary outcome was the need for additional uterotonic drugs. Analyses were performed per protocol. @entity1 , investigators, and data analysts were masked to group assignment. RESULTS: A total of 120 @entity1 were included in analyses (60 in each group). At least one additional uterotonic drug was required in 24 (40%) @entity1 in the placebo group versus 6 (10%) @entity1 in the @entity396 group (relative risk 0.16; 95% confidence interval 0.06-0.44). No adverse effects due to @entity396 were recorded. CONCLUSION: Buccal @entity396 during cesarean delivery reduced the need for additional uterotonic drugs to treat uterine atony. ClinicalTrials.gov:NCT01733329.

Randomized double-blind placebo-controlled trial of buccal XXXX to reduce the need for additional uterotonic drugs during cesarean delivery.

@entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients'] @entity398 :: ('MESH:D010121', 'Chemical') :: ['oxytocin'] @entity396 :: ('MESH:D016595', 'Chemical') :: ['misoprostol']
@entity396 :: (MESH:D016595,Chemical) :: ['misoprostol']
